Last updated: September 8, 2026
Sarclisa, Sanofi’s anti-CD38 monoclonal antibody isatuximab-irfc, is expanding beyond its original relapsed multiple myeloma market. Sanofi reported approximately €440 million in 2023 Sarclisa sales, up from roughly €375 million in 2022. The March 2024 U.S. approval of Sarclisa with bortezomib, lenalidomide and dexamethasone, or VRd, opened a substantially larger newly diagnosed multiple myeloma population. [1][2]
The commercial opportunity is significant but constrained by Johnson & Johnson and Genmab’s dominant Darzalex franchise, increasing use of CAR-T and bispecific antibodies, treatment-center capacity, and the need to establish Sarclisa as a preferred first-line anti-CD38 therapy.
What is Sarclisa and how does it work?
Sarclisa is isatuximab-irfc, an intravenous anti-CD38 monoclonal antibody developed by Sanofi. It binds CD38 on malignant plasma cells and produces direct apoptosis and immune-mediated cell killing through mechanisms that include antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity.
The principal commercial indications are:
| Market |
Sarclisa regimen |
Regulatory status |
| Relapsed or refractory multiple myeloma |
Sarclisa plus pomalidomide and dexamethasone, or Isa-Pd |
U.S. approval in 2020 |
| Relapsed or refractory multiple myeloma |
Sarclisa plus carfilzomib and dexamethasone, or Isa-Kd |
U.S. approval in 2021 |
| Newly diagnosed multiple myeloma in patients ineligible for autologous stem-cell transplant |
Sarclisa plus VRd |
U.S. approval in 2024 |
| Multiple myeloma, Europe and other markets |
Combination regimens vary by jurisdiction |
Approved in multiple regions |
The drug is administered intravenously. The initial schedule generally requires weekly dosing during the first treatment cycle, followed by dosing every two weeks. This creates infusion-center and nursing requirements that may influence product selection against competing subcutaneous or more operationally convenient therapies.
How large is the Sarclisa market?
The addressable market is the global multiple myeloma treatment market, which includes anti-CD38 antibodies, proteasome inhibitors, immunomodulatory drugs, cellular therapies and bispecific antibodies.
Multiple myeloma is a chronic hematologic malignancy with repeated treatment lines. Incidence is lower than for major solid tumors, but treatment duration and sequential therapy produce high annual spending. Global multiple myeloma drug spending is estimated in the multibillion-dollar range, with Darzalex representing the largest branded product in the class.
Sarclisa’s commercial market has three layers:
- Relapsed disease, where the product established its initial presence.
- Newly diagnosed, transplant-ineligible disease, following the VRd approval.
- Potential transplant-eligible and earlier-line uses, subject to clinical and regulatory outcomes.
The first-line opportunity is strategically important because patients beginning therapy can remain on an anti-CD38-containing regimen for extended periods. Penetration in initial therapy can therefore improve both patient acquisition and duration of treatment.
What are Sarclisa’s reported sales and financial trajectory?
Sanofi’s reported Sarclisa sales have increased consistently since launch.
| Fiscal year |
Approximate Sarclisa sales |
Commercial development |
| 2020 |
Approximately €70 million |
Initial launch year |
| 2021 |
Approximately €240 million |
Expansion of relapsed/refractory use |
| 2022 |
Approximately €375 million |
Broader uptake of Isa-Kd and Isa-Pd |
| 2023 |
Approximately €440 million |
Continued growth before first-line U.S. launch |
| 2024 onward |
Growth expected from VRd launch |
First-line opportunity begins contributing |
The sales figures are based on Sanofi annual and quarterly reporting and may differ depending on constant-exchange-rate presentation and reporting period. [1][2]
Sarclisa remains a growth product rather than a core revenue pillar comparable with Sanofi’s Dupixent franchise. Its strategic value is greater than its current sales contribution because the product gives Sanofi an independently controlled multiple myeloma platform with expansion potential across treatment lines.
A reasonable commercial framework is:
- Near term: continued growth from existing Isa-Pd and Isa-Kd use.
- Medium term: accelerated demand from newly diagnosed, transplant-ineligible patients receiving Isa-VRd.
- Longer term: pressure from Darzalex, bispecific antibodies, CAR-T products and eventual biosimilar competition.
The 2024 U.S. first-line approval could materially increase the product’s annual sales ceiling. The magnitude depends on formulary placement, adoption by community oncology practices, physician preference, and whether Sarclisa can displace Darzalex or primarily capture patients who otherwise would not receive an anti-CD38 regimen.
How does Sarclisa compare with Darzalex?
Darzalex, or daratumumab, is Sarclisa’s principal direct competitor. Darzalex is marketed by Johnson & Johnson and Genmab and has a larger clinical, commercial and formulation footprint.
| Category |
Sarclisa |
Darzalex |
| Active ingredient |
Isatuximab |
Daratumumab |
| Target |
CD38 |
CD38 |
| Original U.S. approval |
2020 |
2015 |
| Primary manufacturer |
Sanofi |
Johnson & Johnson and Genmab |
| Administration |
Intravenous |
Intravenous and subcutaneous |
| Key competitive advantage |
Clinical differentiation potential and Sanofi control |
Earlier launch, broader indications, subcutaneous delivery and larger commercial base |
| First-line opportunity |
Sarclisa-VRd approved in 2024 for specified patients |
Darzalex has extensive frontline use across multiple regimens |
| Main risk |
Lower market share and less convenient administration |
Patent and biologic exclusivity exposure over time |
Darzalex’s subcutaneous formulation is a major competitive advantage. It reduces infusion time and can improve treatment-center throughput. Sarclisa is developing a subcutaneous formulation, but commercial impact depends on regulatory approval, clinical comparability and launch timing.
The main strategic question is whether Sarclisa can differentiate through:
- Clinical outcomes in newly diagnosed disease.
- Use in specific patient subgroups.
- Lower administration burden if a subcutaneous version reaches market.
- Contracting and formulary terms.
- Combination sequencing across earlier and later lines.
Without a meaningful delivery or efficacy advantage, Sarclisa is likely to remain the second major anti-CD38 franchise rather than become the class leader.
What did the FDA approve for Sarclisa in 2024?
The FDA approved Sarclisa with bortezomib, lenalidomide and dexamethasone for newly diagnosed multiple myeloma in adults who are not eligible for autologous stem-cell transplant. [3]
The approval was based on the IMROZ phase 3 study, which evaluated isatuximab in combination with VRd followed by isatuximab with lenalidomide maintenance against VRd followed by lenalidomide maintenance. Sanofi reported improved progression-free survival for the Sarclisa-containing regimen.
This approval changes the product’s market position in three ways:
- It moves Sarclisa from primarily relapsed disease into initial therapy.
- It creates an opportunity to influence treatment selection before patients receive multiple prior regimens.
- It gives Sanofi a commercial platform around a four-drug induction and maintenance sequence.
Execution will determine the financial outcome. Four-drug regimens can face adoption barriers because of toxicity management, infusion scheduling, reimbursement, and coordination among community oncology providers.
What exclusivity protects Sarclisa and when could biosimilar competition begin?
Sarclisa is a biologic licensed in the United States on March 2, 2020. The U.S. reference-product biologic exclusivity period is 12 years, creating an earliest statutory biosimilar licensing date of March 2, 2032, subject to the Biologics Price Competition and Innovation Act and any relevant patent litigation. [4][5]
| Protection category |
Key date or status |
| U.S. biologic approval |
March 2, 2020 |
| U.S. reference-product exclusivity |
Generally through March 2032 |
| U.S. Orange Book listing |
Not applicable; biologics are tracked through the Purple Book and patent-disclosure framework |
| Biosimilar pathway |
Possible after statutory exclusivity, subject to patents and litigation |
| European regulatory exclusivity |
Generally eight years of data exclusivity plus two years of market protection, with a potential additional year for a qualifying new indication |
The exact commercial entry date for a biosimilar cannot be determined from regulatory exclusivity alone. Patent litigation, settlement agreements, manufacturing readiness, interchangeability status and launch economics will affect timing.
Because Sarclisa is an antibody with complex manufacturing and analytical requirements, biosimilar development will require substantial clinical, analytical and process investment. That barrier is meaningful but not permanent. Anti-CD38 antibody demand could support several biosimilar programs once the market becomes sufficiently large.
What patent litigation and Paragraph IV risks affect Sarclisa?
Sarclisa does not have an Orange Book patent profile in the same way as a small-molecule drug because biologics are not listed in the Orange Book. Biosimilar applicants use the BPCIA patent-exchange process, often called the patent dance, rather than a conventional Paragraph IV certification.
The principal future litigation risks are likely to involve:
- Antibody composition and sequence claims.
- Methods of treating multiple myeloma.
- Combination regimens.
- Dosing schedules.
- Formulations and stabilization.
- Manufacturing cell lines and purification processes.
- Subcutaneous delivery systems.
A biosimilar applicant could challenge patents before or after the reference product’s statutory exclusivity period. Sanofi may seek injunctions, damages or negotiated launch timing. The commercial value of a patent depends on claim scope, validity, enforceability, written-description support, enablement and whether non-infringing biosimilar manufacturing routes are available.
Publicly available information does not establish a conventional Sarclisa Paragraph IV dispute comparable to major small-molecule generic litigation. The more relevant future event is a BPCIA biosimilar patent dispute.
What manufacturing and formulation barriers protect Sarclisa?
Sarclisa is a recombinant monoclonal antibody requiring mammalian-cell production, purification, viral clearance, formulation control and sterile fill-finish operations. These requirements create higher entry costs than standard oral generics.
Manufacturing barriers include:
- Cell-line development and stable expression.
- Protein aggregation control.
- Glycosylation comparability.
- Impurity and host-cell protein control.
- Sterile injectable production.
- Cold-chain distribution.
- Analytical similarity testing.
The product’s intravenous presentation also creates an administration burden. That burden is a commercial disadvantage versus subcutaneous daratumumab, but it can protect the established product from rapid substitution if physicians value continuity and treatment familiarity.
A subcutaneous Sarclisa formulation would improve convenience and could support a longer commercial life. It could also require new formulation, device, manufacturing and patent protection.
Which companies are challenging Sarclisa in the multiple myeloma market?
The competitive landscape includes branded antibodies, generic backbone drugs, cellular therapies and emerging immune therapies.
| Competitor |
Company |
Competitive position |
| Darzalex |
Johnson & Johnson and Genmab |
Dominant anti-CD38 competitor |
| Empliciti |
Bristol Myers Squibb and AbbVie |
Earlier-generation antibody with smaller market position |
| Revlimid and generic lenalidomide |
Bristol Myers Squibb and generic manufacturers |
Major backbone therapy |
| Kyprolis |
Amgen |
Proteasome inhibitor used in combination regimens |
| Velcade and generic bortezomib |
Johnson & Johnson and generic manufacturers |
Core proteasome inhibitor |
| Carvykti |
Johnson & Johnson and Legend Biotech |
BCMA-directed CAR-T therapy |
| Abecma |
Bristol Myers Squibb and 2seventy bio |
BCMA-directed CAR-T therapy |
| Tecvayli |
Johnson & Johnson |
BCMAxCD3 bispecific antibody |
| Elrexfio |
Pfizer |
BCMAxCD3 bispecific antibody |
| Talvey |
Johnson & Johnson |
GPRC5DxCD3 bispecific antibody |
CAR-T and bispecific products are more direct threats in heavily pretreated disease than in initial therapy. Their use can reduce the number of later-line patients available for antibody combinations. Manufacturing capacity, patient eligibility, referral logistics and adverse-event management currently limit their use, but the competitive pressure is increasing.
How strong is the Sarclisa patent and commercial estate?
Sarclisa’s commercial estate is strongest in regulatory positioning and clinical expansion rather than in a simple composition-of-matter monopoly.
Key strengths include:
- Twelve years of U.S. biologic exclusivity from the 2020 approval.
- A first-line U.S. indication approved in 2024.
- Multiple combination regimens.
- A long-duration treatment market.
- Sanofi’s global commercial infrastructure.
- Potential formulation and dosing patents.
Key weaknesses include:
- Darzalex’s earlier launch and larger physician base.
- Darzalex’s subcutaneous presentation.
- Increasing competition from BCMA-directed therapies.
- Intravenous administration requirements.
- Limited differentiation if pivotal trials show similar outcomes.
- Future biosimilar feasibility for a validated antibody target.
The patent estate should be evaluated claim by claim. The commercial value of method-of-use patents may be high if they cover widely adopted first-line regimens, but those claims can be vulnerable to validity and non-infringement challenges. Combination patents may also face limitations where individual components are already standard therapies.
What generic or biosimilar launch scenarios exist for Sarclisa?
The most likely sequence is:
Scenario one: controlled post-2032 biosimilar entry
One or more biosimilars launch after U.S. reference-product exclusivity expires. Price erosion is initially moderate because oncology practices may retain the branded product for established patients, while payers direct new starts to lower-cost alternatives.
Scenario two: patent-delayed entry
Sanofi asserts formulation, manufacturing or method-of-use patents and negotiates settlements that delay biosimilar entry beyond the statutory exclusivity date.
Scenario three: limited biosimilar competition
The market supports only a small number of biosimilar entrants because development costs are high and Darzalex already dominates the anti-CD38 segment. Sarclisa could retain a premium position if it maintains meaningful clinical or delivery differentiation.
Scenario four: class-level substitution
Biosimilar pressure combines with increased CAR-T and bispecific use. In that case, Sarclisa faces erosion not only from lower-priced isatuximab products but also from declining use of anti-CD38 antibodies in later lines.
What is the revenue exposure for Sanofi?
Sarclisa is strategically important but represents a small portion of Sanofi’s consolidated revenue compared with Dupixent and vaccines. Its direct financial exposure is concentrated in:
- Product sales growth.
- Development and manufacturing costs.
- Commercial investment in hematology.
- Clinical expansion costs.
- Potential royalty and collaboration economics.
- Long-term margin impact from biosimilar competition.
The 2024 first-line approval increases the probability that Sarclisa can become a billion-euro-scale product, but that outcome depends on share capture from Darzalex and broad uptake of Isa-VRd. A more conservative path would involve continued growth in relapsed disease and incremental first-line adoption, producing a durable but secondary anti-CD38 franchise.
What licensing deals affect Sarclisa?
Sanofi is the principal commercial owner and developer of Sarclisa. The product was developed through Sanofi’s internal oncology portfolio rather than through a high-profile external licensing structure comparable with the Genmab-Johnson & Johnson relationship for daratumumab.
The absence of a major external royalty burden can support product economics, although Sanofi still bears clinical development, manufacturing and commercialization costs. Any future regional licensing, co-commercialization, or formulation partnership would alter the revenue split and development obligations.
What is the regulatory status and geographic coverage of Sarclisa?
Sarclisa has regulatory approvals in the United States, European Union and other international markets for specified multiple myeloma combinations. The commercial opportunity is geographically uneven.
| Region |
Market considerations |
| United States |
Highest pricing potential; strong Darzalex competition; 2024 first-line approval expands opportunity |
| European Union |
Centralized approval with national reimbursement negotiations; price controls are more material |
| Japan |
Regulatory and reimbursement requirements can affect uptake and dosing economics |
| China and other markets |
Local access, pricing and oncology infrastructure influence adoption |
| Emerging markets |
Lower pricing and limited infusion capacity constrain revenue |
Geographic expansion can increase patient volume but may lower average realized price. Sanofi’s global infrastructure supports distribution, while local reimbursement decisions remain decisive.
Key Takeaways
- Sarclisa is Sanofi’s isatuximab-irfc anti-CD38 biologic for multiple myeloma.
- Reported sales increased from approximately €375 million in 2022 to approximately €440 million in 2023.
- The March 2024 FDA approval of Sarclisa plus VRd created a first-line growth opportunity in newly diagnosed, transplant-ineligible multiple myeloma.
- Darzalex remains the leading anti-CD38 competitor because of its earlier launch, broader indication base and subcutaneous formulation.
- U.S. biologic exclusivity generally extends through March 2032, although patent litigation could affect biosimilar timing.
- Sarclisa is not an Orange Book-listed small molecule. Future biosimilar disputes would proceed through the BPCIA framework.
- CAR-T and bispecific antibodies create increasing pressure in later-line disease.
- Sarclisa’s most important commercial test is whether the 2024 first-line approval can produce meaningful share against Darzalex.
- A subcutaneous formulation or additional strong early-line data could improve the product’s long-term trajectory.
- The product has a credible path to continued growth but remains a challenger franchise in the anti-CD38 market.
FAQs
When did Sarclisa first receive FDA approval?
The FDA approved Sarclisa on March 2, 2020, in combination with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior therapies.
Is Sarclisa a biosimilar or a reference biologic?
Sarclisa is an original biologic reference product. It is not a biosimilar. Future competitors would need to pursue the FDA biosimilar pathway.
Does Sarclisa have a subcutaneous formulation?
Sarclisa’s marketed U.S. presentation has been intravenous. A subcutaneous formulation would be commercially important because Darzalex Faspro already offers subcutaneous administration.
Can Sarclisa replace Darzalex?
Sarclisa can compete with Darzalex in selected regimens, but replacing Darzalex across the class would require superior or clearly differentiated clinical outcomes, administration convenience, reimbursement terms, or treatment durability.
What is the largest financial risk to Sarclisa?
The largest risk is failure to gain meaningful first-line share against Darzalex while later-line use declines because CAR-T and bispecific therapies capture more patients.
References
-
Sanofi. (2024). 2023 universal registration document and annual financial report. Sanofi.
-
Sanofi. (2023). 2022 annual report. Sanofi.
-
U.S. Food and Drug Administration. (2024, March 20). FDA approves isatuximab-irfc with VRd for newly diagnosed multiple myeloma. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2020). Sarclisa prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
